全文获取类型
收费全文 | 21616篇 |
免费 | 1832篇 |
国内免费 | 436篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 442篇 |
妇产科学 | 527篇 |
基础医学 | 1232篇 |
口腔科学 | 877篇 |
临床医学 | 2870篇 |
内科学 | 3255篇 |
皮肤病学 | 385篇 |
神经病学 | 1374篇 |
特种医学 | 260篇 |
外国民族医学 | 3篇 |
外科学 | 2095篇 |
综合类 | 1767篇 |
一般理论 | 3篇 |
预防医学 | 2014篇 |
眼科学 | 177篇 |
药学 | 3102篇 |
4篇 | |
中国医学 | 1945篇 |
肿瘤学 | 1446篇 |
出版年
2024年 | 87篇 |
2023年 | 570篇 |
2022年 | 832篇 |
2021年 | 1171篇 |
2020年 | 1051篇 |
2019年 | 1066篇 |
2018年 | 1031篇 |
2017年 | 969篇 |
2016年 | 839篇 |
2015年 | 833篇 |
2014年 | 1844篇 |
2013年 | 2356篇 |
2012年 | 1226篇 |
2011年 | 1202篇 |
2010年 | 949篇 |
2009年 | 933篇 |
2008年 | 1003篇 |
2007年 | 895篇 |
2006年 | 821篇 |
2005年 | 678篇 |
2004年 | 598篇 |
2003年 | 450篇 |
2002年 | 394篇 |
2001年 | 302篇 |
2000年 | 235篇 |
1999年 | 205篇 |
1998年 | 173篇 |
1997年 | 169篇 |
1996年 | 124篇 |
1995年 | 91篇 |
1994年 | 117篇 |
1993年 | 79篇 |
1992年 | 73篇 |
1991年 | 61篇 |
1990年 | 57篇 |
1989年 | 76篇 |
1988年 | 53篇 |
1987年 | 46篇 |
1986年 | 23篇 |
1985年 | 40篇 |
1984年 | 33篇 |
1983年 | 25篇 |
1982年 | 18篇 |
1981年 | 17篇 |
1980年 | 12篇 |
1979年 | 18篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
目的 探讨电针复合靶控输注(Target Controlled Infusion, TCI)在单肺通气食管癌开胸手术麻醉中的应用价值。方法 选取于我院拟行单肺通气食管癌开胸切除手术患者60例作为研究对象。随机将其分为试验组与对照组,对照组30例采取气管插管全麻及TCI靶控输注维持麻醉深度,试验组30例则在对照组方案基础上辅助电针麻醉,记录两组患者手术麻醉时间、药物用量、苏醒时间、并发症;以及术前(TⅠ)、插管前即刻(TⅡ)、插管后1 min(TⅢ)、切皮即刻(TⅣ)、去骨时(TⅤ)、拔管即刻(TⅥ)时平均动脉压(MAP)、平均心率(HR)、BIS值;术前、术后1天、术后3天简易智能精神状态检查量表(MMSE);并于麻醉诱导前(T0)、手术开始2 h(T1)、术后1天(T2)、术后3天(T3)时抽取患者外周静脉血检测IL-1β、IL-6、IL-10、TNF-α浓度。结果 试验组手术用时、麻醉时间略低于对照组,但差异无统计学意义(P>0.05),试验组异丙酚、舒芬太尼用量以及苏醒时间均明显低于对照组(P<0.05);TⅡ时两组平均动脉压(Mean Arterial Pressure, MAP)、心率(Heartrate, HR)较术前明显降低,且试验组MAP明显低于对照组(P<0.05),但两组TⅡ时HR比较无显著差异(P>0.05);TⅢ、TⅥ时对照组MAP、HR明显高于TⅠ时,而试验组MAP、HR与TⅠ比较无显著差异(P>0.05)。术后1天、3天试验组简易智能精神状态检查量表(Mini-Mental State Examination, MMSE)评分低于对照组,有显著性差异(P<0.05)。T1、T2、T3时试验组白介素-1β(IL-1β)、白介素-6(IL-6)、肿瘤坏死因子(Tumor Necrosis Factor-α, TNF-α)水平明显低于对照组(P<0.05),白介素-10(IL-10)水平明显高于对照组(P<0.05)。结论 采用电针复合TCI靶控输注麻醉方案可有效提升单肺通气食管癌开胸手术麻醉效果,能够降低患者术后认知功能障碍发生风险。 相似文献
2.
3.
《BJU international》2006,98(Z2):9-12
The tamsulosin oral‐controlled absorption system (OCAS®) is a new tablet formulation of the α1‐adrenoceptor (α1‐AR) antagonist tamsulosin, which is used for treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). The tablet uses the OCAS technology, which was specifically designed to give a more continuous 24‐h release of tamsulosin, resulting in a more consistent and continuous 24‐h plasma concentration, a lower maximum plasma concentration (Cmax) and an independence of pharmacokinetics (PKs) on food intake. It was expected that the improved PK profile would translate into a better control of day‐ and night‐time symptoms of BPH and a lower risk of adverse events. Phase I PK studies showed that tamsulosin OCAS indeed has a flattened PK profile with a lower Cmax and a more stable and consistent 24‐h concentration of tamsulosin, independent of food intake, compared to conventional tamsulosin. A study combining γ‐scintigraphy and PK analysis of blood samples confirmed that the improved PK profile of tamsulosin OCAS is attributed to the tablet being consistently and continuously released throughout the entire gastrointestinal tract, including the colon. 相似文献
4.
Four clinical trials of porcine islet transplantation have been reported, and there are verbal reports that clinical trials on much larger scales are continuing in centers in China and Russia. The four reported trials are briefly reviewed and, in the light of the present status of experimental islet xenotransplantation, consideration is given to whether such trials are currently justified. The Ethics Committee of the International Xenotransplantation Association has (1) emphasized the need for encouraging studies in non-human primates before clinical trials should be undertaken, (2) mandatory monitoring for the transfer of porcine microorganisms, and (3) careful regulation and oversight by recognized bodies. Other aspects of the topic, such as the need for informed consent, are briefly discussed. We conclude that, at the present time, more data documenting convincing efficacy, focused on clinically applicable immunosuppressive regimens, are needed to justify the initiation of closely monitored clinical trials. A clinical trial may then be justified even though the potential risk to the patients, and possibly for society, will not be zero. 相似文献
5.
Guerra de Hoyos JA, Andres Martin Mdel C, Bassas y Baena de Leon E, Vigara Lopez M, Molina Lopez T, Verdugo Morilla FA, Gonzalez Moreno MJ. Pain. 2004 Dec;112(3): 289-98.The objective of the study is to compare the efficacy of electro-acupuncture with placebo-acupuncture for the treatment of shoulder pain. This study comprised of a prospective, randomized, placebo controlled trial, with independent evaluator set in a Public primary care clinic in Spain. The participants are patients aged from 25 to 83 years with shoulder pain. Patients were randomly allocated to two treatments over eight weeks, with electro-acupuncture or skin non-penetrating placebo-acupuncture, both able to take diclofenac if needed for intense pain. Primary outcome measure was the difference between groups in pain intensity (visual analogue scale – VAS). Secondary outcomes were differences between groups in pain intensity measured by Lattinen index, in range of motion (goniometer), functional ability (SPADI), quality of life (COOP-WONCA charts), NSAIDS intake, credibility (Borkoveck and Nau scale) and global satisfaction (10 points analogue scale). Assessments were performed before, during and three and six months after treatment. At six month follow-up after treatment the acupuncture group showed a significantly greater improvement in pain intensity compared with the control group [VAS mean difference 2.0 (95 % CI 1.2–2.9)]. The acupuncture group had consistently better results in every secondary outcome measure than the control group. Acupuncture is an effective long-term treatment for patients with shoulder pain (from soft tissues lesions) in a primary care setting. q2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. 相似文献
6.
Judith D. Goldberg Arnold I. Weiss Kenneth J. Koury 《Journal of clinical periodontology》1986,13(5):411-414
In order to make effective use of the statistical theory of design of clinical trials for chronic diseases such as periodontal disease, certain issues must be considered. Any clinical trial requires that the disease definition be well-specified; that patient eligibility be explicit; that the observation times be explicit; that the duration and endpoint of therapy be specified; that the duration of subsequent followup observation be specified; and that the unit of observation (e.g., tooth, set of teeth, patient) be defined. In a chronic disease, the potential biases that can readily be introduced by self-selection of patients who enter the trial and/or who return for subsequent observation become more important, because subjects are required to remain on treatment and/or observation for prolonged periods. Further, the cyclical nature of some chronic diseases may require special attention to baseline definitions of active disease and disease outcome. These issues are illustrated with examples from clinical trials of hypertension, breast cancer screening, and Polycythemia Vera. Implications for periodontal disease are discussed. 相似文献
7.
Effect of impact exercise on bone mineral density in elderly women with low BMD: a population-based randomized controlled 30-month intervention 总被引:4,自引:3,他引:1
Raija Korpelainen Sirkka Keinänen-Kiukaanniemi Jorma Heikkinen Kalervo Väänänen Juha Korpelainen 《Osteoporosis international》2006,17(1):109-118
Evidence of the effect of exercise on bone loss comes mainly from studies in voluntary postmenopausal women, and no population-based, long-term interventions have been performed. The purpose of this population-based, randomized, controlled trial was to determine the effect of long-term impact exercise on bone mass at various skeletal sites in elderly women with low bone mineral density (BMD) at the radius and hip. Participants ( n =160) were randomly assigned to 30 months either of supervised and home-based impact exercise training or of no intervention. The primary outcome measures were femoral neck, trochanter and total hip BMD, and the secondary outcomes were bone density measures at the radius and calcaneum. Outcomes were assessed at baseline, 12 months and 30 months using blinded operators. The analyses were performed on an intention-to-treat analysis. Mean femoral neck and trochanter BMD decreased in the control group [–1.1%, 95% confidence interval (CI) –0.1% to –2.1% and –1.6%, 95% CI –0.4% to –2.7%], while no change occurred in the exercise group. Mean trochanter BMC decreased more in the control group (–7.7%, 95% CI –9.7% to –5.6% vs. –2.9%, 95% CI –5.3 to –0.9). There were six falls that resulted in fractures in the exercise group and 16 in the control group during the 30-month intervention ( P =0.019). A significant bone loss occurred in both groups at the radius and calcaneum. In multivariate analysis, weight gain was associated with increased BMD and BMC at all femur sites both in the exercise group and in the pooled groups. In conclusion, impact exercise had no effect on BMD, while there was a positive effect on BMC at the trochanter. Exercise may prevent fall-related fractures in elderly women with low bone mass.There was no conflict of interest. 相似文献
8.
目的分别应用三针锁针加压器外固定和空心拉力钉内固定疗法治疗股骨颈骨折,探讨股骨颈骨折最佳治疗方法.方法应用三针锁针加压器外固定治疗股骨颈骨折63例,其中男24例,女39例;年龄55~89岁,平均(64.5±3.2)岁;Garderl Ⅰ型2例,Ⅱ型15例,Ⅲ型38例,Ⅳ型8例.应用空心拉力钉内固定治疗63例,其中男29例,女34例;年龄45~76岁,平均(62.2±2.9)岁;Garden Ⅰ型4例,Ⅱ型24例,Ⅲ型28例,Ⅳ型7例.对其疗效进行分析.结果126例除2例死亡外均得到随访.115例愈合,其中10例股骨头坏死.外固定组愈合58例,股骨头坏死4例,死亡1例;内固定组愈合57例,股骨头坏死6例,死亡1例.根据Harris功能评定标准评价疗效,外固定组62例中优24例,良26例,可8例,差4例,优良率80.65%;内固定组62例中优23例,良27例,可6例,差6例,优良率80.65%.Harris评分外固定组平均(80.40±1.21)分,内固定组平均(79.14±1.47)分,两组Harris评分比较差异无统计学意义(P>0.05).结论采用内外固定治疗股骨颈骨折疗效无明显差异,但外固定创伤小、费用低、可早期离床;而采用拉力钉内固定器医疗成本高,卧病时间相对较长,且需二次手术取内固定钉. 相似文献
9.
10.
The Department of Health has funded a national diabetes network to support clinical research. The network will facilitate recruitment into clinical trials and has been widely welcomed by clinicians. However, if the network is to reach its full potential, all those involved will need to advocate a change in attitude towards clinical trials and research, encouraging participation and contribution of data. Clinicians need to be willing to take a proactive view about research studies, and to encourage patients to adopt a positive and altruistic attitude towards trial participation. The future of trials and other important clinical research in the UK may depend on it. 相似文献